The world's top 15 pharmaceutical enterprises gathered for the first time to enter the China market of the Expo and become a "battleground"

　　The fifth China International Import Expo is in full swing. As the earliest "full" exhibition area, the medical equipment and health care museum is still popular this year. With an exhibition area of about 70000 square meters, more than 350 enterprises from more than 33 countries and regions have "crowded" into the exhibition.

　　At this Expo, Johnson&Johnson, Pfizer, Roche Pharmaceuticals, Alberville, Novartis, MSD, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, AstraZeneca, Takeda Pharmaceuticals, Lilly, Bayer, Gilead, Amgen and other top 15 pharmaceutical giants in the world gathered for the first time in five years. As the second largest pharmaceutical and health market in the world, China has become the "battleground" for multinational pharmaceutical enterprises. At this year's Expo, many pharmaceutical enterprises gathered their "first show", "first push" and "first launch" to show the world their innovative technology strength.

　　"The Expo not only builds a platform to promote global innovation exchange and development, but also fully demonstrates China's determination to expand openness and share development opportunities." Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical and President of Takeda China, said, "Takeda Pharmaceutical is confident in the long-term development and growth potential of China's medical industry".

　　Since the first Expo in 2018. Takeda Pharmaceutical has approved 9 innovative products in China, and these products have been displayed at previous Expo. In recent years, Takeda Pharmaceutical's innovative drugs and breakthrough therapies have set new records in the speed of being approved for listing in China.

　　At this Expo, Sanofi vaccine brought Beyfortus (nirsevimab), the world's first and only respiratory syncytial virus (RSV) prevention method that can be widely used in newborns and infants, which is also the world's first show of this product; Takeda Pharmaceuticals made a collective appearance with eight innovative products and breakthrough therapies that are the world's first and best of their kind in the core fields of digestion, cancer, rare diseases, etc; Bayer brings a new mechanism of action to treat chronic heart failure; Janssen, a pharmaceutical subsidiary of Johnson&Johnson, exhibited revolutionary therapies for improving multiple myeloma for the first time.

　　For multinational pharmaceutical enterprises, it is not the first time that global cutting-edge innovation achievements have been intensively presented at the Expo. Thanks to the "spillover" effect of entering the Expo, many of the world's leading innovative products participating in the Expo accelerated their approval, listing and access in China. From "exhibits to commodities", they constantly refreshed their "new identity in China", benefiting more Chinese patients and people.

　　This year, the targeted human anti interleukin-5 (IL-5) monoclonal antibody that once again appeared on the stage of entering the Expo is a successful case of GlaxoSmithKline's use of the entering the Expo effect. In 2021. after entering the "debut" of the Expo, Xinke will be approved by the State Food and Drug Administration for the treatment of adult eosinophilic granulomatous polyangitis (EGPA) within two weeks, and will issue its first prescription in July this year, rapidly realizing the identity leap from "debut" to "first place".

　　At present, China's biopharmaceutical industry is undergoing industry reform led by "innovation". Taking advantage of the opportunities of China's pharmaceutical market and entering the stage of the Expo, multinational pharmaceutical enterprises are also frequently opening various cooperation with local enterprises, accelerating the localization process and creating a new "friend circle" of medical ecology.

　　Song Weiqun, senior vice president of Johnson&Johnson in the world and chairman of China, said that the strong "spillover effect" of the five years of Jinbo not only promoted "exhibits to become commodities", but also promoted Johnson&Johnson from "exhibitors to investors". For example, the new generation of antibacterial Weiqiao absorbable suture of Johnson&Johnson Medical Technology, which had landed in the Expo as an imported product, was successfully localized in Johnson&Johnson Suzhou Industrial Park in January this year, filling the industry gap in this production field in China.

　　Zhang Heping, the head of Sanofi vaccine in Greater China, said that Sanofi had been investing in the Chinese market for 40 years. Sanofi introduced China's first and only foreign-funded vaccine factory in Shenzhen, and established China's first international vaccine innovation center. "Chinese local vaccine companies are gradually accelerating international cooperation, and a large number of domestic and foreign scientists and professional technicians have entered the field of Chinese vaccines. I believe that the development of Chinese vaccines will be better and better in the future, and will reach the world's advanced level."

　　"In the future, China will become one of the important sources of global pharmaceutical innovation." Shan Guohong said that China's pharmaceutical innovation is being integrated into the global innovation system, and Takeda Pharmaceutical will promote the introduction of global innovation achievements to China at a faster speed. China plays a crucial role in Takeda's R&D strategy, and has become one of the four key R&D regions comparable to the United States, Japan and Europe.

Shandong Zhushi Pharmaceutical Group Co., Ltd., founded in 2003, has more than 5000 registered employees. After years of development, it has developed into a diversified industrial cluster integrating medical devices, polymers, cosmetics, health food, daily necessities and biological reagent production, enterprise management consulting and training, real estate economy, pharmaceutical transportation, pharmaceutical printing, etc.

Adhering to the concept of life, health and happiness, the Group provides you with full chain health services.

HOT

NEW